
TYRX Inc (AKA: Advanced Materials Design, LLC ~TYRX Pharma Inc) Profile last edited on: 2/27/19
CAGE:
UEI:
Business Identifier: Resorbable polymeric biomaterials: surgical-site infections (SSIs) and inflammatory tissue-reaction associated with implanted medical devices. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 12
County: Middlesx
Congr. District: 12
County: Middlesx
Public Profile
Originally dba TYRX Pharma, Inc. and renamed as TYRX Inc., as of January 2014 the firm operates as a subsidiary of Medtronic plc. Engaged in the design, development, and commercialization of resorbable polymeric biomaterials, TYRX offers absorbable and non-absorbable antibacterial envelopes/implantable devices for cardiovascular, cosmetic surgical, and other pharmaceutical applications. The company offers products to stabilize cardiac implantable devices; to reduce surgical site infection rates and treatment costs for high-risk patients. Anchored in IP licensed from Rutgers University, covering a broad range of resorbable materials and drug delivery technology as well as having Working relationships with various lare corporate entities, the firm offers PIVIT CRM, a mesh based pouch, which contains antibacterial agents to help provide protection from microbial colonization of the generator or defibrillator during and immediately after surgical implant. The company also provides AIGISRx Flat, an antibacterial product that provides protection against infections associated with implanted pacemakers and defibrillators.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
50-74Revenue Range
5M-7.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2004 | 1 | NIH | $100,000 | |
Project Title: Polymer System for Treatment of Post Surgical Pain |
Key People / Management
Robert White -- President & CEO
Pamela Amsbaugh -- Controller
Mark Citron -- Vice President, Regulatory Affairs and Quality Systems
William Edelman -- Chief Executive Officer
Ray Imp -- Chief Financial Officer
Joachim B Kohn -- Founder
Daniel Lerner -- Chief Medical Officer
Randy Mansfield -- VP Marketing
William McJames -- Vice President of Product Development
Arikha Moses -- Chief Operating Officer
Satish Pulapura -- Vice President, Advanced Products, Director, Polymer Research & Development
Jordan Warshafsky -- Former President
Jeff Wolf -- Founder
Pamela Amsbaugh -- Controller
Mark Citron -- Vice President, Regulatory Affairs and Quality Systems
William Edelman -- Chief Executive Officer
Ray Imp -- Chief Financial Officer
Joachim B Kohn -- Founder
Daniel Lerner -- Chief Medical Officer
Randy Mansfield -- VP Marketing
William McJames -- Vice President of Product Development
Arikha Moses -- Chief Operating Officer
Satish Pulapura -- Vice President, Advanced Products, Director, Polymer Research & Development
Jordan Warshafsky -- Former President
Jeff Wolf -- Founder